Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021;15(3):166-168.
doi: 10.5582/ddt.2021.01061.

Aducanumab: The first targeted Alzheimer's therapy

Pan Yang  1 , Fusheng Sun  2
Affiliations
Free article

Aducanumab: The first targeted Alzheimer's therapy

Pan Yang et al. Drug Discov Ther. 2021.
Free article

Abstract

Alzheimer's disease (AD) is an irreversible brain disorder associated with severe progressive dementia and is characterized by deposits of amyloid plaques in the brain. Over the past 20 years, the mortality of strokes and heart disease has decreased, but deaths from AD have increased. The four drugs used clinically to treat AD can only relieve symptoms but cannot slow the progression of the disease. Aducanumab, a human monoclonal antibody that preferentially binds to aggregated amyloid-β to reduce the number of amyloid plaques and slow disease progression, was approved to treat AD by the US Food and Drug Administration on June 7, 2021. It is the first disease-modifying therapy for AD, but there is considerable controversy regarding the drug's approval. Aducanumab offers hope for millions of patients.

Keywords: Alzheimer's disease; aducanumab; amyloid-β; clinical trials.

PubMed Disclaimer

MeSH terms